List of investigational sleep drugs
Appearance
This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Insomnia[edit]
GABAA receptor potentiators[edit]
- EVT-201 – GABAA receptor positive allosteric modulator[1]
- Lorediplon (GF-015535-00) – GABAA receptor positive allosteric modulator [2]
- Zuranolone (SAGE-217) – GABAA receptor positive allosteric modulator [3]
Orexin receptor antagonists[edit]
- Seltorexant (MIN-202, JNJ,42847922, JNJ-922) – selective OX2 receptor antagonist [4]
- Vornorexant (ORN-0829, TS-142) – dual OX1 and OX2 receptor antagonist [5]
Melatonin receptor agonists[edit]
- Piromelatine (Neu-P11) – melatonin receptor agonist and 5-HT1A and 5-HT1D receptor agonist [6]
Nociceptin receptor agonists[edit]
- Sunobinop (IMB-115, IT-1315, S-117957, V-117957) – nociceptin receptor agonist [7][8]
Hypersomnia/narcolepsy[edit]
Orexin receptor agonists[edit]
- Danavorexton (TAK-925) – OX2 receptor-selective agonist via IV infusion[1][9]
- TAK-994 – OX2 receptor agonist pill (orally available)[10][1]
Monoaminergics[edit]
- Flecainide/modafinil (THN-102) – modafinil (dopamine reuptake inhibitor) and flecainide (antiarrhythmic) combination [11]
- Mazindol controlled release (NLS-1001, NLS-1) – norepinephrine-predominant serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI)[12]
- Reboxetine (AXS-12) – norepinephrine reuptake inhibitor (NRI) [13]
GHB receptor agonists[edit]
GABAA receptor inhibitors[edit]
- Pentylenetetrazole (BTD-001) – GABAA receptor negative allosteric modulator [14]